The Failure of Solanezumab - How the FDA Saved Taxpayers Billions

N Engl J Med. 2017 May 4;376(18):1706-1708. doi: 10.1056/NEJMp1701047.

Authors

Chana A Sacks¹, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliation

¹ From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

PMID: 28467878
DOI: 10.1056/NEJMp1701047

No abstract available

MeSH terms

Alzheimer Disease / drug therapy*
Antibodies, Monoclonal, Humanized / economics
Antibodies, Monoclonal, Humanized / therapeutic use*
Cost Savings
Dementia / drug therapy
Drug Approval* / legislation & jurisprudence
Drug Costs*
Humans
Randomized Controlled Trials as Topic
Treatment Failure
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
solanezumab